発血性心疾患のチェレーション療法:ランダム化制御試験
Merril L Knudtson1, D George Wyse, P Diane Galbraith
1Foothills Medical Center, 1403 29th St NW, Calgary, Alberta, Canada T2N 2T9. knudtson@shaw.ca
JAMA
|February 2, 2002
まとめ
エチレネジアミネトラエセチア酸 (EDTA) を用いたチェレーション治療は,安定した心不全性疾患の患者において,運動不全症の値または生活の質を改善しませんでした. このランダム化試験では,プラセボと比較して有意な利点が見つかりませんでした.
科学分野:
- 心臓病学 心臓病学
- 代替医療の研究 代替医療の研究
- クリニック・トライアル 臨床試験
背景:
- EDTAによるチェレーション療法は,心筋不全性疾患の一般的な,しかし実証されていない代替治療法です.
- 患者のアウトカムを改善する効果は依然として論争の的だ.
研究 の 目的:
- 安定した缺血性心疾患の患者における運動による缺血症の値と生活の質に対するEDTAケレーション療法の影響を評価する.
- 現在のEDTAプロトコルが好ましい効果をもたらすかどうかを判断する.
主な方法:
- ダブルブラインド,ランダム化,プラセボ対照試験は,冠動脈疾患または心筋梗塞と安定した胸痛と診断された84人の患者を対象に実施されました.
- 参加者は,体重調整によるEDTAケレーション療法またはプラセボを15週間にわたって週2回受け,その後3ヶ月間毎月治療を受けた.
- 主なアウトカム指標は,27週間のフォローアップでトレッドミルのテストで1mmのSTうつ状態への時間の変化でした.
主要な成果:
- EDTAケレーション群とプラセボ群の両方で,運動時間の改善が示されました (63秒対54秒).
- グループ間の統計的に有意な差は認められなかった (9秒の差;P =.69).
- 運動能力と生活の質のスコアの改善は,両方の治療腕で比較可能でした.
結論:
- この研究では,安定した缺血性心疾患の患者の運動耐性または生活の質を改善するためにEDTAケレーション療法の使用を支持する証拠は見つかりませんでした.
- 結果は,この患者集団においてEDTAケレーション療法がプラセボより効果的ではないことを示しています.
関連する概念動画
01:17Ischemic Heart Disease: Overview
3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
01:26Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
01:27Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
01:30Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
01:28Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741